Opaleye Management Inc. Blueprint Medicines Corp Transaction History

Opaleye Management Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $4.81 Million - $8.22 Million	-100,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $333,650 - $412,950	-5,000 Reduced 4.76%	100,000 $8 Million
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $1.46 Million - $2.03 Million	-20,000 Reduced 16.0%	105,000 $7.71 Million
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $367,700 - $489,000	-5,000 Reduced 3.85%	125,000 $11.8 Million
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $8.28 Million - $14.7 Million	-170,000 Reduced 56.67%	130,000 $10.4 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $2.95 Million - $3.92 Million	-50,000 Reduced 14.29%	300,000 $23.4 Million
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $15.2 Million - $25.3 Million	-250,000 Reduced 41.67%	350,000 $22.2 Million
Q1 2018 May 14, 2018	SELL	$73.28 - $102.95 $9.89 Million - $13.9 Million	-135,000 Reduced 18.37%	600,000 $55 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $31.1 Million - $51.2 Million	735,000	735,000 $51.2 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.